Syngenix

Syngenix is a biotechnology company specializing in synthetic biology and targeted drug delivery systems. Originally founded as SynGenix Ltd in Cambridge, the company developed the ProVector platform, which utilizes axonal transport for the selective delivery of therapeutics to the nervous system, primarily for treating neuropathic pain. In its current operations, Syngenix has expanded into genomic diagnostics and biomanufacturing, utilizing RNA-Seq classifiers for early cancer risk prediction and CRISPR-engineered yeast strains for efficient API production. The company's history includes significant collaborations with major pharmaceutical firms like GlaxoSmithKline and foundational support from prominent venture capital firms such as Amadeus Capital Partners.